The analysis shows that the new vaccine offers better protection against Omicron than Moderna’s original vaccine, Spikevax, producing nearly double the neutralising antibody levels.
The vaccine candidate targets two of the virus variants, including Omicron. It met all primary endpoints in the phase 2/3 trial and was well-tolerated by the 437 study participants.
The vaccine contains specific mRNA elements for the spike protein associated with both the Omicron variant and the original SARS-CoV-2 virus. If approved, it could be used as a second booster dose in future vaccine roll-out programmes…
